Objective: To assess overall non-adherence to the treatment among patients with Crohn's disease (CD) and ulcerative colitis (UC). Patients and methods: 396 inflammatory bowel disease (IBD) patients were enrolled in the study (200 males, 196 females, 210 CD, 186 UC) and fulfilled the questionnaire to assess their nonadherent behaviour during the treatment. The data was analysed using factor analysis. Results: Overall intentional non-adherence was reported by 32% of patients. A 12% of patients reported they at least once discontinued the treatment. Voluntary dose reducing was reported by 19% of patients. An 11% of patients occasionally non-refill the medication in time. There were no differences in intentional adherence between males and females, disease type, previous bowel surgery, marital, smoking and non-smoking statuses. A 42% of patients reported unintentional non-adherence. Factor analysis proved non-adherent patients are more likely to have a higher activity of the disease ( τ = 0.109, p = 0.008). Conclusions: The overall intentional non-adherence is relatively high among IBD patients and a gastroenterologist's attention should be focused on it. Our results stimulate discussion how to improve education of the patients with inflammatory bowel disease and accent importance of the maintenance therapy to them.
Introduction
Pharmacotherapy of inflammatory bowel disease (IBD) targets symptomatic as well as asymptomatic phases of the disease and may be effective in remission induction and maintenance. 1 A few published papers documented a poor adherence rate outside the clinical trial settings.
Patient's adherence to treatment is defined as the rate of cooperation in following the physician's prescriptions and recommendations. 9 A sufficient adherence is one of the key factors of treatment success, the published papers documented an increased risk of flare-up among non-adherent patients. 3, 6 Non-adherence logically means a lack of cooperation in following the physician's prescriptions and recommendations. 9 In spite of progress in the pharmacotherapy in IBD, many patients still flare and non-adherence to the treatment may be the reason of this. 4 Non-adherence to pharmacotherapy is nowadays taken for one of the most serious problems for modern medicine to face. 9, 10 The doctor-patient relationship, treatment regimen and other disease-related factors play a key role in the adherence process. The treatment duration, several adverse effects of the medications, or symptom reduction, or even disappearance, during the remission phase play also it's specific role. [10] [11] [12] Besides this adherence rapidly decreases with the increasing number of prescribed medicines and is also inversely related to the number of doses per day. 12, 13 In our study we assessed rate and most frequent reasons of non-adherence to the pharmacotherapy of IBD. We used a questionnaire survey among patients with IBD, followed up in 10 gastroenterological centers in the Czech Republic.
Patients and methods
Patients with the diagnosis of IBD (Crohn's disease and ulcerative colitis), followed up in the gastroenterological ambulances, were enrolled in the study between August 2005 and February 2006. The examined cohort comprised of 396 patients from 10 gastroenterological units from allover the Czech Republic. A detailed characteristics of the examined cohort is displayed in Tables 1 and 2 . During one ambulatory visit of a gastroenterologist, patient was asked for participation in the questionnaire survey. The patients were briefly informed about adherence problems and the study's character. They were presented an anonymous questionnaire, where they could express their own experience with following their gastroenterologist's recommendations and orders. They were clearly guaranteed that no personal data are to be stated and that the responses in no way will influence their further treatment options. Those who agreed with participation were enrolled. Patients were not given advanced notice about the study before visiting the IBD Unit. After agreement attending gastroenterologist provided information about the disease type (CD or UC), activity, and localization to the special protocol which was a part of the questionnaire. The disease activity was simplified for the purpose of statistical analysis to a three-grade scale (remission, chronically active, flare). Subsequently patient was given the questionnaire to complete it. After that, he sealed the questionnaire in the envelope and when leaving the ambulance, he left it at the designated place at the reception. After termination of the study the questionnaires were collected from the gastrocenters and jointly unsealed at the Department of Social and Clinical Pharmacy at the Faculty of Pharmacy. This ensured full anonymity to the patient.
Key questions focused on adherence, adapted from a previously published paper, 1 were included with additional questions to complete a 30-item questionnaire. The key questions on adherence targeted at treatment discontinuation, dose reduction, regularity in using medicines and refilling medicines. Additional data was of demographic character, knowledge on disease and medicines and registered adverse drug effects (data not shown).
In our study, patients were considered to be non-adherent if they stated to have at least one of the possible nonadherent behaviours in the questionnaire: a) not using the prescribed medications at all; b) using the prescribed medications only prior to visiting a gastroenterologist; c) using the prescribed medications only when their feeling of wellbeing deteriorates; d) treatment discontinuation without their gastroenterologist's consent; e) dose reduction without their gastroenterologist's consent; f) not refilling their medications on time.
Prior to the study launch the questionnaire was validated in the pilot group of IBD patients, followed up in the Gastroenterological Centre of the University Hospital in Prague. 8 
Statistical analysis
The data was processed by the statistical software SPSS®, version 11.5. For the characteristics of the tested cohort, descriptive statistics were used.
The χ 2 (Chi square) testing was performed to compare frequencies of demographic variables and disease characteristics between adherent and non-adherent groups. The interview data were processed by the factor analysis, a method that enables the reduction of a large body of data into a few independent factors. The factor analysis allows the researcher to keep the maximum amount of information, while finding relationships between derived factors and additional variables.
14 To correlate individual adherence factors with other clinical and demographic variables, the Kendall's Tau coefficient values were used.
A p value of b 0.05 was considered statistically significant. All tests were two-tailed.
Results
A total of 396 IBD patients participated in the questionnaire survey. At least one period of treatment discontinuation during the treatment was admitted by 50 patients (12.6%). The most frequent reasons were: feeling well and therefore supposing there is no need to continue with pharmacological treatment (54%) and adverse drug effects occurrence (16%). In women pregnancy or breast feeding were also reasons for intentional treatment discontinuation (10%).
At least one intentional dose reduction without gastroenterologist's consent was in the questionnaire stated by 78 respondents (19.7%). The most frequent reasons were: feeling well (64.1%) and running out of the medication and therefore a necessity to reduce doses in order to save it till the next visit of a gastroenterologist (17.9%). Adverse drug effects occurrence was again one of the frequent reasons of dose reducing (11.5%), just as pregnancy and breast feeding in women (3.8%).
Forty five respondents (11.3%) admitted they minimally once did not refill their medications on time. The mean time of being without the medications in these patients was 7 days.
Only 9 patients (2.2%) stated they use their medications only when well feeling deteriorates and only 2 patients (0.5%) use it just prior to visiting the IBD Unit. No one reported complete disregard to the prescribed treatment.
Generally, at least one form of intentional non-adherence was stated by 129 respondents (32.5%).
Unintentional non-adherence (occasionally forgotten prescribed daily doses) was reported by 169 patients (42.6%).
As for additional questions, 88 patients (22.2%) stated they detected at least once an adverse effect of the prescribed IBD therapy drugs.
In patients with CD receiving aminosalicylates the nonadherence rate at any timepoint was 34% vs. 40% in patients on immunosupressants vs. 38% in patients on systemic corticosteroids vs. 31% in patients on topical corticosteroids. The differences were statistically insignificant.
The non-adherence tended to increase in CD with disease activity (30% in remission vs. 42% in chronically active vs. 42% in flare), however did not reach statistical significance.
Similar statistically not significant differences were found in patients with UC. The overall non-adherence at any time was 32% in patients on aminosalicylates vs. 40% in those on immunosupressants vs. 39% on systemic corticosteroids vs. 42% on topical corticosteroids.
The differences in activity in CD was not of statistical significance (33% in remission vs. 31% in chronically active vs. 25% in flare).
293 patients (73.9%) rate their treatment as quite effective, 44 (11.1%) take it for mildly effective, 57 patients (14.5%) were not able to score it and only 2 respondents (0.5%) evaluated their treatment as completely ineffective. 25.7% of the patients seek additional information about the prescribed drugs. As for disease, 40.1% of the patients seek additional information.
By means of χ 2 testing no statistically significant relationships in adherence between the two diseases, genders, smokers and non-smokers, marital status and other demographic variables were found.
Factor analysis
The 11 questions, crucial for adherence, were proceeded using the factor analysis. The four independent factors were identified (Table 3 ). These factors can be taken for certain character traits of adherence in the examined cohort.
1. A factor characterizing general non-adherence to treatment. A low regularity in using medicines and frequent doses omitting is remarkable. It is also characterized by treatment discontinuation, doses reduction and non-refilling the medicines in time. 2. A factor characterizing patient's depreciation to the treatment. Non-refilling the medicines in time and irregular using of them is considerable. 3. A factor characterizing patient's consistency in treatment. It is characterized by a lack of treatment discontinuation and voluntary increase in dose, when well feeling deteriorates. An active searching for additional information on medicines and disease is considerable. 4. A factor characterizing intentional non-adherence and a lack of confidence to the treatment. Irregularity in medicines using is considerable, just as treatment discontinuation and doses reducing. A very low rating of treatment effectiveness, but an active seeking additional information on disease and medications, are remarkable.
The factors were subsequently correlated with additional questionnaire data (personal, demographic, disease, and medication data), using the Kendall's Tau coefficient values τ, and a significance level (p value).
Adverse drug effects occurrence positively correlates with Factor 3 (τ = 0.119, p = 0.005) and also with Factor 4 (τ = 0.107, p = 0.011). Both factors are characterized by active seeking additional information on disease and medicines by patients.
Factor 4, characterizing intentional non-adherence and a lack of confidence to the treatment, is in a positive correlation with disease activity (τ = 0.109, p = 0.008). Patients with a history of non-adherent behaviour are of a higher risk of flare-up.
In addition, by means of factor analysis, statistically significant relationships between non-adherence and other characteristics like disease type, previous bowel surgery, gender, marital or smoking statuses, were not found.
Discussion
Insufficient adherence to the pharmacological treatment of IBD may be a reason of it's failure. A complicacy and complexity of a process of patient's adherence to the treatment unables using a single method for it's research. 9 A few previously published papers address this problems. [1] [2] [3] [4] [5] [6] [7] [8] In case of studies using analytical determination of active substance or a metabolite in biological material, Van Hees and Van Tongeren assessed non-adherence to the sulfasalazine treatment upon 12%. 2 Other studies analytically demonstrated the absence of mesalamine in 12% 5 and in 13% 7 of examined patient cohorts. Using patient medication records from the pharmacy, the percentage of fully adherent patients was stated at only 40%. Patients were designated as non-adherent if they used less than 80% of the prescribed doses during the past 6 months. 4 Sewitch et al. stated intentional non-adherence at 36.5% of the examined cohort. 1 Shale et al. proved retrospectively ingestion of less than 80% of prescribed medicines in 43% of patients.
5 35% of non-adherent patients were identified in the study of Lopez San Roman. 7 Kane et al. suggest male gender and single status are risk factors for adherence. 4 In the study of Shale et al., younger patients, patients educated beyond the age of 16 years, patients having full-time employment, being prescribed a three-times-a-day regimen, taking no other medications and perceiving their medication as ineffective, were identified as non-adherent. 5 A higher degree of intentional non-adherence in the study by Lopez San Roman was associated with greater patient's depression and patient-physician discordance, with patients having longer-standing IBD, patients who trusted their physician less and who considered themselves to be less informed about their treatment. 7 Cerveny et al. proved adherence tends to decrease with younger age of patients and interestingly also with higher education of patients. It was also documented that adverse drug effects impair patient's attitude to the treatment and substantially decrease adherence to the treatment. 8 Our study failed to prove any statistically significant relationships between adherence to the treatment and gender, marital status, previous bowel surgery, disease type and it's localization and smokers and non-smokers.
Differences in methodologies of our and previously published studies unable more detailed comparison of results. Another barrier of comparison is definition of non-adherence, that is arbitrarily set in each study. However generally, based upon the output of descriptive statistics, we can conclude the ratio of intentionally non-adherent patients in our cohort is similar like described in previously published papers. As for unintentional non-adherence, we report the ratio in our study to be smaller, than previously published. In our study we did not focus further on the unintentional nonadherence, as we assumed this type of non-adherence is not as risky as the intentional one that is of greater implication and needs to be addressed. 7 By means of factor analysis, we failed to confirm that adherence rate depends on gender, disease type and other demographic variables. We report a very strong influence of adverse drug effects on adherence and, contrary to previously published papers which do not address this issue, we found it adherence impairing. Intentional nonadherent behaviour due to adverse drug effects was the second most often reported reason in the questionnaire. In addition, adverse drug effects were independently proven by the factor analysis to affect a patient's confidence in treatment. Adverse drug effects occurrence was frequently reported in patients actively searching for additional information on disease and medications. In case of medicines these information logically include those on adverse drug effects, knowledge of which may impair adherence to the treatment. Patients may be more conscious of adverse drug effects and therefore they may observe them on themselves. Adverse drug effects of drugs for IBD should be in the scope of a gastroenterologist and should be taken account of. Our another very important finding is non-adherent patients are likely to suffer from more severe disease. This confirms results of previously published studies adherence to the pharmacotherapy is important for maintaining remission in patients with IBD. 3, 6, 8 Results from factor analysis suggest adherence to the treatment in the examined cohort may be strongly influenced by patients knowledge on disease and pharmacotherapy. These findings open a discussion of optimal education of patients on these topics by a gastroenterologist. Particular attention should be paid to information on adverse drug effects, as also results from factor analysis.
Generally, if there is a lack of a treatment success, a gastroenterologist should think among others of possible non-adherent behaviour of a patient. Patients should be intensively instructed about the importance of maintenance therapy and adherence to the treatment in order to achieve the therapeutic goal -reduced frequency of relapse.
Our research results may be related to the entire IBD population in the Czech Republic. The examined cohort was formed by patients followed up in 10 gastroenterological units from allover the country and the number of cohort subjects was not inconsiderable.
Conclusion
At least one form of intentional non-adherence was documented in 32.5% of the examined cohort of 396 IBD patients. The intentional non-adherence is characterized by treatment discontinuation and doses reduction, both without a gastroenterologist's consent. The most frequent reason was feeling well. Adverse drug effects also play important role in adherence process. Another important form of nonadherent behaviour by patients is that of not refilling their prescriptions on time.
The factor analysis documented a higher degree of disease activity among non-adherent patients. Adherence to the treatment was also proven to be impaired by adverse drug effects.
Adherence to the treatment seems to be influenced by a patient's disease and medication awareness. Gastroenterologists should educate IBD patients regarding the importance of maintenance therapy and adherence to the treatment generally.
Lowering of intentional non-adherence may be one of possible ways how to improve effectiveness of IBD therapy.
